Changeflow GovPing Healthcare & Life Sciences Non-Human Animals Expressing pH-Sensitive Immun...
Routine Notice Added Final

Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260107928A1, filed December 16, 2025, covering genetically modified non-human animals that express pH-sensitive immunoglobulin variable domains. The application names John McWhirter, Lynn Macdonald, Joel H. Martin, and Andrew J. Murphy as inventors, with Application No. 19421956. The invention relates to immunoglobulin genes comprising histidines in CDR regions, N-terminal regions, and loop 4 regions, enabling pH-sensitive antigen binding.

“Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 268 changes logged to date.

What changed

The USPTO published a patent application for genetically modified non-human animals engineered to express pH-sensitive immunoglobulin variable domains containing histidine substitutions in CDR regions, N-terminal regions, and loop 4 regions. The application covers animals with modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes.

Biotechnology and pharmaceutical companies engaged in antibody engineering or protein therapeutic research should monitor this application for potential implications on pH-sensitive immunoglobulin technologies.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences

Application US20260107928A1 Kind: A1 Apr 23, 2026

Inventors

John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy

Abstract

Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.

CPC Classifications

A01K 67/0275 A01K 67/0278 C07K 16/00 C12N 15/8509 A01K 2217/072 A01K 2217/075 A01K 2217/15 A01K 2227/105 A01K 2267/01 C07K 2317/10 C07K 2317/21 C07K 2317/92 C07K 2317/94 C12N 2800/204

Filing Date

2025-12-16

Application No.

19421956

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260107928A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Biotechnology research Genetic modification Immunoglobulin development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!